These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 17393902)

  • 41. Management of protamine allergy with bivalirudin during coronary artery revascularization.
    Koster A; Rosendahl U; von Hodenberg E; Ennker J
    Ann Thorac Surg; 2010 Jul; 90(1):276-7. PubMed ID: 20609794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anticoagulant therapy during cardiopulmonary bypass.
    Yavari M; Becker RC
    J Thromb Thrombolysis; 2008 Dec; 26(3):218-28. PubMed ID: 18931979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Bleeding complications of anticoagulant therapy].
    Gumulec J; Kessler P; Procházka V; Brejcha M; Penka M; Zänger M; Machytka E; Klement P
    Vnitr Lek; 2009 Mar; 55(3):277-89. PubMed ID: 19378860
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mid-term Clinical Outcomes of Immediate Protamine Use Following Elective Percutaneous Coronary Interventions.
    Kubota M; Sakakura K; Yamamoto K; Taniguchi Y; Tsukui T; Seguchi M; Wada H; Momomura SI; Fujita H
    Int Heart J; 2020 Sep; 61(5):865-871. PubMed ID: 32921667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multivessel coronary thrombosis resulting from heparin induced thrombocytopenia.
    Iqbal R; Mulvihill NT; Nolan B; Crean PA
    Ir Med J; 2007 Sep; 100(8):569-71. PubMed ID: 17955717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of hemorrhagic events in patients receiving anticoagulant therapy.
    Love DG
    J Thromb Thrombolysis; 1999 Apr; 7(2):149-52. PubMed ID: 10364766
    [No Abstract]   [Full Text] [Related]  

  • 47. [Long-term application of percutaneous cardiopulmonary support system without systemic heparinization].
    Miura M; Fukuju T
    Kyobu Geka; 2004 Feb; 57(2):115-8. PubMed ID: 14978904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Precipitation of protamine by cefazolin.
    Ng HP; Koh KF
    Anesth Analg; 2002 Sep; 95(3):785. PubMed ID: 12198083
    [No Abstract]   [Full Text] [Related]  

  • 49. Development of protamine hollow-fiber device for extracorporeal heparin removal.
    Liang JF; Emregul E; Yang VC
    Blood Purif; 2004; 22(2):198-202. PubMed ID: 15044818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Continuous infusion of factor VIIIc during heart surgery in a patient with haemophilia A.
    De Bels D; Demeere JL; Dugauquier J; Louis P; Van der Vorst E
    Eur J Anaesthesiol; 2004 Dec; 21(12):984-6. PubMed ID: 15719864
    [No Abstract]   [Full Text] [Related]  

  • 51. Percutaneous transthoracic ventricular puncture for diagnostic and interventional catheterization.
    Lim DS; Ragosta M; Dent JM
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):915-8. PubMed ID: 18383174
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis.
    Kalaska B; Sokolowska E; Kaminski K; Szczubialka K; Kramkowski K; Mogielnicki A; Nowakowska M; Buczko W
    Eur J Pharmacol; 2012 Jul; 686(1-3):81-9. PubMed ID: 22579410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of protamine after radiofrequency catheter ablation: a pilot study.
    Patel AA; Clyne CA; Henyan NN; White CM; Zembrowski BF; Migeed M; Yarlagadda R; Kluger J; Coleman CI
    J Interv Card Electrophysiol; 2007 Mar; 18(2):155-8. PubMed ID: 17318446
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Must heparin be neutralized following open-heart operations?
    Castaneda AR
    J Thorac Cardiovasc Surg; 1966 Nov; 52(5):716-24. PubMed ID: 5955183
    [No Abstract]   [Full Text] [Related]  

  • 55. [Measurement of activated clotting time during cardiopulmonary bypass in infective endocarditis patients].
    Jiang L; Yu JF
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):167-9. PubMed ID: 17344611
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Protamin-sulfate in cardiac surgery: between Scilla and Haribda].
    Charnaia MA; Morozova IuA; Gladysheva VG
    Khirurgiia (Mosk); 2006; (12):45-9. PubMed ID: 17419491
    [No Abstract]   [Full Text] [Related]  

  • 57. Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content.
    Chawla LS; Moore G; Seneff MG
    Obes Surg; 2004 May; 14(5):695-8. PubMed ID: 15186641
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anticoagulants and their reversal.
    Schulman S; Bijsterveld NR
    Transfus Med Rev; 2007 Jan; 21(1):37-48. PubMed ID: 17174219
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibodies against heparin-protamine complexes: Effect and clinical relevance.
    Beckerman Z; Cohen O
    J Thorac Cardiovasc Surg; 2015 Oct; 150(4):974-5. PubMed ID: 26320779
    [No Abstract]   [Full Text] [Related]  

  • 60. Glycosaminoglycan Neutralization in Coagulation Control.
    Sobczak AIS; Pitt SJ; Stewart AJ
    Arterioscler Thromb Vasc Biol; 2018 Jun; 38(6):1258-1270. PubMed ID: 29674476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.